arrow
H

Heinz-Josef Lenz

University of Southern California
H指数:106
被引数:5.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer

激活内吞通路对结直肠癌亚型和治疗敏感性的分层作用

2026-10-190
OAAI
MammaTrace – a tumor naïve cell-free DNA methylation test for minimal residual disease in breast cancer

MammaTrace——一种用于乳腺癌微小残留病灶的肿瘤 naive 细胞游离 DNA 甲基化检测

2026-07-230
OA
Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset

食管癌(EC)的基因组分析识别出组蛋白甲基转移酶的复发突变作为一个独特亚群

2026-07-110
OA
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis

Tucatinib联合曲妥珠单抗治疗化疗难治性、HER2阳性、RAS野生型转移性结直肠癌(MOUNTAINEER):最终分析

2026-01-120
OAAI
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer

炎症和突变负担与nivolumab或ipilimumab联合疗法的疗效在结直肠癌中存在差异关联。

2025-10-060
OAAI
GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer

GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer

2025-08-240
OAAI
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: a combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)

FOLFIRI联合贝伐珠单抗或西妥昔单抗在奥沙利铂为基础辅助治疗患者中的疗效:FIRE-3和CALGB/SWOG 80405 (Alliance)联合分析

2025-08-050
PRE
Optimizing participant and community engagement in cancer genomic sequencing research

优化癌症基因组测序研究中参与者和社区的参与度

2025-06-110
PRE
Depletion of oxysterol-binding proteins by OSW-1 triggers RIP1/RIP3-independent necroptosis and sensitization to cancer immunotherapy

OSW-1耗竭oxysterol-binding protein可触发RIP1/RIP3非依赖性坏死性凋亡,并增强对癌症免疫治疗的敏感性。

2025-05-060
OA
Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy
2025-01-080
OA